Deficient mismatch repair and BRAF-V600E-mutated metastatic colorectal cancer responds to nivolumab therapy after progression under bevacizumab plus FOLFIRI

• Published in: Journal of cancer research and therapeutics Vol. 20; no. 6; pp. 1878 - 1881
• Main Authors: Chen, Po-Jung, Yeh, Yung-Sung, Tsai, Hsiang-Lin, Huang, Ching-Wen, Yang, Sheau-Fang, Wang, Jaw-Yuan
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer - Medknow 01.10.2024; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Edition: 2
• Subjects: Cancer therapies; Case Report; Chemotherapy; Colorectal cancer; DNA mismatch repair; Gene mutations; Health aspects; Immunotherapy; Metastasis; Monoclonal antibodies; Targeted cancer therapy; Taiwan; BRAF-V600E mutation; metastatic colorectal cancer; nivolumab; deficient mismatch repair (dMMR)

ABSTRACT Nivolumab, a PD-1 immune checkpoint inhibitor, has been demonstrated to be clinically effective in patients with deficient mismatch repair (dMMR) and BRAF-V600E-mutated metastatic colorectal cancer (mCRC). We present the case of an 81-year-old Taiwanese woman with mCRC who responded favorab...